Clinical Trials Logo

Recurrent Colon Cancer clinical trials

View clinical trials related to Recurrent Colon Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT01814501 Active, not recruiting - Clinical trials for Recurrent Rectal Cancer

Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab

Start date: February 1, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well panitumumab and combination chemotherapy works in treating patients with metastatic colorectal cancer previously treated with combination chemotherapy and bevacizumab. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving panitumumab and combination chemotherapy together may kill more tumor cells

NCT ID: NCT00826540 Active, not recruiting - Clinical trials for Recurrent Rectal Cancer

Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Start date: September 2009
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving sorafenib together with bevacizumab works in treating patients with metastatic colorectal cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Sorafenib and bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib together with bevacizumab may kill more tumor cells